Updates are available Expression of concern dated 2026-02-23
Click to view Expression of concern: https://doi.org/10.1038/s42255-021-00491-8
-
Authors
Xu, Qixia
Fu, Qiang
Li, Zi
Liu, Hanxin
Wang, Ying https://orcid.org/0000-0002-2571-9367
Lin, Xu
He, Ruikun
Zhang, Xuguang
Ju, Zhenyu
Campisi, Judith
Kirkland, James L. https://orcid.org/0000-0003-1676-4905
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81472709, 31671425, 31871380, 82130045)
- License Information
-
More Information
Article History
Received: 14 April 2021
Accepted: 13 October 2021
First Online: 6 December 2021
Change Date: 30 September 2025
Change Type: Clarification
Change Details: Editor's note: Readers are alerted that the authors have identified errors in the data presented in this article. Further editorial action will be taken if appropriate once the original data have been validated and the impact of the required changes to the article has been reviewed by the Editors.
Change Date: 23 February 2026
Change Type: ExpressionOfConcern
Change Details: An Editorial Expression of Concern to this paper has been published:
Change Details: https://doi.org/10.1038/s42255-026-01487-y
Competing interests
: By-Health funds research on senolytics in Y.S.’s laboratory. Y.S., Q.X., R.H. and X.Z. are named inventors on a technical patent related to senolytic screening and pharmacological evaluation (202011428651.2). Q.F. is the founder and CEO of Shandong Cellogene Pharmaceutics, for which Y.S. serves as a scientific advisor. J.C. is a scientific founder of Unity Biotechnology, which develops senolytic therapies, and holds patents related to the induction and detection of senolysis. J.L.K. has financial interest related to this research, with patents on senolytic drugs held by the Mayo Clinic. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies. The remaining authors declare no competing interests.
